12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Referencer
Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan
DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S. Role of nonmyeloablative
allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative
malignancies. J Clin Oncol. 2002;20(19):4022-31.
Corradini, P., Tarella, C., Olivieri, A., Gianni, A.M., Voena, C., Zallio, F., Ladetto, M., Falda, M., Lucesole, M.,
Dodero, A., Ciceri, F., Benedetti, F., Rambaldi, A., Sajeva, M.R., Tresoldi, M., Pileri, A., Bordignon, C. & Bregni,
M. (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and
molecular remissions in patients with poor-risk hematologic malignancies. Blood, 99, 75 82.
Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., Milpied, N., Rio, B., Cahn, J.Y.,
Molina, L., Laporte, J.L., Guilhot, F. & Kuentz, M. (1999) Allogeneic bone marrow transplantation in aggres-sive
non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the
SFGM database. Societ Francaise de Greffe de Moelle. British Journal of Haematology, 107, 154 161
Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC,
Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell
transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br-J-Haematol. 2005
Oct; 131(2): 223-30
Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B,
Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising
salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous
transplantation. J Clin Oncol. 2004;22(12):2419-23
Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR,
Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus
HM, van-Besien K. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience
relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow
Transplant Registry. Blood. 2004 Dec 1; 104(12): 3797-803
Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R,
Sonneveld P, Gisselbrecht C, VanDerLelie H, Chauvin F. Time to relapse has prognostic value in patients with
aggressive lymphoma enrolled onto the Parma trial. J-Clin-Oncol. 1998 ; 16(10): 3264-9
Gustaaf W. van Imhoff, Bronno van der Holt, Marius A. MacKenzie, Mars B. van't Veer, Pierre W. Wijermans,
Gerrit J. Ossenkoppele, Harry C. Schouten, Pieter Sonneveld, Monique M.C. Steijaert, Philip M. Kluin, Hanneke
C. Kluin-Nelemans, Leo F. Verdonck . Impact of Three Courses of Intensified CHOP Prior to High-Dose
Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk,
Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative
Group Studies 27 and 40. JCO 2005;23;16: 3793-3801
C Haioun, E Lepage, C Gisselbrecht, Y Bastion, B Coiffier, P Brice, A Bosly, B Dupriez, C Nouvel, H Tilly, P
Lederlin, P Biron, J Briere, P Gaulard, F Reyes . Benefit of autologous bone marrow transplantation over
68